AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31969547 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency (LF) group: Nanoseal application at baseline and 3 months
Number of subjects: 129
Study 31969547 — intervention group
Group type: COMPARATOR
Intervention: Control group: no application of Nanoseal
Number of subjects: 129
Study 29081255 — intervention group
Group type: EXPERIMENTAL
Intervention: Benda‐14 (intravenous bendamustine, 120 mg/m2 on days 1 and 15, repeated every 4 weeks for a total of 6 cycles)
Number of subjects: 46
Study 29081255 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 46
Study 27732620 — intervention group
Group type: EXPERIMENTAL
Intervention: Embedded Figures Test (EFT)
Number of subjects: 371
Study 27732620 — intervention group
Group type: COMPARATOR
Intervention: Simulation groups (control, naïve simulation, symptom-coached simulation, test-coached simulation)
Number of subjects: 371
Study 27732620 — intervention group
Group type: EXPERIMENTAL
Intervention: EFT index for prediction of feigned ADHD
Number of subjects: 371
Study 24630880 — intervention group
Group type: EXPERIMENTAL
Intervention: bare Cheatham-Platinum stents (bCP)
Number of subjects: 120
Study 24630880 — intervention group
Group type: EXPERIMENTAL
Intervention: covered Cheatham-Platinum stents (cCP)
Number of subjects: 120
Study 22433939 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oxytocin
Number of subjects: 144
Study 22433939 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone vaginal pessary (Propess®)
Number of subjects: 144
Study 20551234 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer‐assisted personal interview (CAPI)
Number of subjects: 2351
Study 20551234 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer‐assisted self‐interview (CASI)
Number of subjects: 2351
Study 20551234 — intervention group
Group type: COMPARATOR
Intervention: Pen and paper interview (PAPI)
Number of subjects: 2351
Study 18789533 — intervention group
Group type: COMPARATOR
Intervention: Distance activities during 2 hours of daily patching
Number of subjects: 425
Study 18789533 — intervention group
Group type: EXPERIMENTAL
Intervention: Near activities during 2 hours of daily patching
Number of subjects: 425
Study 18789533 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Distance and Near activities)
Number of subjects: 425
Study 18789533 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hours of daily patching (for children with severe amblyopia)
Number of subjects: 425
Study 15910489 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (0.75 microg/kg/h for 3 h after a bolus of 0.75 microg/kg body weight)
Number of subjects: 14
Study 15910489 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 14
Study 12578430 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 30
Study 12578430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10499694 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of Care Testing (PCT)
Number of subjects: 180
Study 10499694 — intervention group
Group type: COMPARATOR
Intervention: Central Laboratory Testing
Number of subjects: 180
Study 10499694 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of Care Testing (PCT) among discharged patients
Number of subjects: 180
Study 10499694 — intervention group
Group type: COMPARATOR
Intervention: Central Laboratory Testing among admitted patients
Number of subjects: 180
Study 9180977 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ondansetron (4 mg) administered 1 hour before induction and additional doses at 8 and 16 hours later
Number of subjects: 30
Study 9180977 — intervention group
Group type: COMPARATOR
Intervention: Oral metoclopramide (5 mg) administered under the same conditions
Number of subjects: 30
Study 1918565 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 15
Study 1918565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1918565 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD boys
Number of subjects: 15
Study 31812457 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroactive Interference (RI) manipulation task
Number of subjects: 0
Study 31812457 — intervention group
Group type: COMPARATOR
Intervention: Control task (simple guilty)
Number of subjects: 0
Study 31812457 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RI and control)
Number of subjects: 0
Study 31309929 — intervention group
Group type: EXPERIMENTAL
Intervention: ClientBot (immediate feedback on use of open questions and reflections)
Number of subjects: 151
Study 31309929 — intervention group
Group type: COMPARATOR
Intervention: Control group (initial education and encouragement on the skills)
Number of subjects: 151
Study 28019072 — intervention group
Group type: EXPERIMENTAL
Intervention: gemigliptin
Number of subjects: 132
Study 28019072 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 132
Study 27436289 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education programme delivered by GPs after a 2-day interactive workshop
Number of subjects: 241
Study 27436289 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control Group)
Number of subjects: 241
Study 27436289 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education programme delivered by GPs
Number of subjects: 241
Study 24404816 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring arm
Number of subjects: 0
Study 24404816 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm
Number of subjects: 0
Study 23029969 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing exercise at 6 breaths/min (0.1 Hz) for one month
Number of subjects: 36
Study 23029969 — intervention group
Group type: COMPARATOR
Intervention: Control group (no breathing exercise)
Number of subjects: 36
Study 18634717 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 En% casein-custard
Number of subjects: 25
Study 18634717 — intervention group
Group type: COMPARATOR
Intervention: 10 En% casein-custard
Number of subjects: 25
Study 17499470 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (QUE)
Number of subjects: 0
Study 17499470 — intervention group
Group type: COMPARATOR
Intervention: Clozapine (CLO) as internal standard
Number of subjects: 0
Study 15688822 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant intraperitoneal chemotherapy with 50 mg of cisplatinum for washing the peritoneal cavity and 20 mg/m2 of cisplatinum intraperitoneally for the first four days after surgery.
Number of subjects: 8
Study 15688822 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group).
Number of subjects: 8
Study 15688822 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant intraperitoneal chemotherapy.
Number of subjects: 8
Study 11738120 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) infusions
Number of subjects: 4
Study 11738120 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivariate mixed‐effects model
Number of subjects: 4
Study 9848527 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 143
Study 9848527 — intervention group
Group type: COMPARATOR
Intervention: Access flap alone
Number of subjects: 143
Study 9848527 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR
Number of subjects: 143
Study 9848527 — intervention group
Group type: COMPARATOR
Intervention: Access flap
Number of subjects: 143
Study 7863464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloricromene (100mg gastroresistant capsules twice a day for 7 days)
Number of subjects: 24
Study 7863464 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 24
Study 2792540 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration catheter
Number of subjects: 30
Study 2792540 — intervention group
Group type: COMPARATOR
Intervention: Tissue biopsy forceps
Number of subjects: 30
Study 406300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cromolyn sodium solution (4% solution, 5.2 mg into each nostril 6 times daily)
Number of subjects: 66
Study 406300 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 66
Study 31519202 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCOVA method with assumed correlation of 0.50
Number of subjects: 7173
Study 31519202 — intervention group
Group type: COMPARATOR
Intervention: Analysis of POST treatment means method
Number of subjects: 7173
Study 31519202 — intervention group
Group type: EXPERIMENTAL
Intervention: CHANGE method
Number of subjects: 7173
Study 31519202 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of covariance (ANCOVA)
Number of subjects: 7173
Study 31519202 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean correlation between baseline and follow-up PROM assessments
Number of subjects: 7173
Study 27196995 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Serum (UCS)
Number of subjects: 105
Study 27196995 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Serum (AS)
Number of subjects: 105
Study 27196995 — intervention group
Group type: COMPARATOR
Intervention: Artificial Tears (AT)
Number of subjects: 105
Study 27196995 — intervention group
Group type: EXPERIMENTAL
Intervention: UCS and AS
Number of subjects: 105
Study 27196995 — intervention group
Group type: EXPERIMENTAL
Intervention: AS and UCS
Number of subjects: 105
Study 25648379 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide anesthesia (2 L/min nitrous oxide and 1 L/min oxygen)
Number of subjects: 59
Study 25648379 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide-free anesthesia (2 L/min air and 1 L/min oxygen)
Number of subjects: 59
Study 25648379 — intervention group
Group type: COMPARATOR
Intervention: Comparison of nitrous oxide vs nitrous oxide-free
Number of subjects: 59
Study 24324084 — intervention group
Group type: EXPERIMENTAL
Intervention: ifosfamide-gemcitabine (IG)
Number of subjects: 693
Study 24324084 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine, ifosfamide, cisplatin (GIP)
Number of subjects: 693
Study 24324084 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel, cisplatin (DP)
Number of subjects: 693
Study 21299294 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit advice plus carbon‐monoxide level feedback
Number of subjects: 160
Study 21299294 — intervention group
Group type: COMPARATOR
Intervention: Quit advice plus leaflet (control)
Number of subjects: 160
Study 19659979 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide at a dose of 300 mg/day for 1 week, gradually reduced thereafter.
Number of subjects: 60
Study 19659979 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 40 mg daily for 2 weeks, tapered by 10 mg every 2 weeks.
Number of subjects: 60
Study 16952213 — intervention group
Group type: EXPERIMENTAL
Intervention: Milligan-Morgan haemorrhoidectomy
Number of subjects: 225
Study 16952213 — intervention group
Group type: COMPARATOR
Intervention: Ferguson haemorrhoidectomy
Number of subjects: 225
Study 15307695 — intervention group
Group type: EXPERIMENTAL
Intervention: Qilian decoction (QLD) given orally, one dose taken twice a day
Number of subjects: 62
Study 15307695 — intervention group
Group type: COMPARATOR
Intervention: Control group (hypoglycemic agent in routine)
Number of subjects: 62
Study 11780351 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrinsic positive end-expiratory pressure (PEEPe) at varying levels (0%, 40%, 60%, 80%, 100% of PEEPi, dynz)
Number of subjects: 10
Study 11780351 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrinsic positive end-expiratory pressure (PEEPe) at 80% and 100% of PEEPi, dynz
Number of subjects: 10
Study 11780351 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrinsic positive end-expiratory pressure (PEEPe)
Number of subjects: 10
Study 9280714 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg/d)
Number of subjects: 11
Study 9280714 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (200 mg/d)
Number of subjects: 11
Study 9280714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 mg/d)
Number of subjects: 11
Study 9280714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8343915 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% EMLA cream (25 mg/mL of lidocaine and prilocaine)
Number of subjects: 25
Study 8343915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 2883575 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril (2.5 to 40 mg per day)
Number of subjects: 253
Study 2883575 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 253
Study 31925970 — intervention group
Group type: EXPERIMENTAL
Intervention: Human disease network (HDN) analysis of disease treatment cost
Number of subjects: 1000000
Study 31231923 — intervention group
Group type: COMPARATOR
Intervention: Topical capsaicin (Zostrix HP 0.075%) only (CAP)
Number of subjects: 20
Study 31231923 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin with preheating (CAP + HEAT)
Number of subjects: 20
Study 31231923 — intervention group
Group type: COMPARATOR
Intervention: Topical nonsensitizing placebo cream (CON)
Number of subjects: 20
Study 28432757 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Number of subjects: 402
Study 28432757 — intervention group
Group type: COMPARATOR
Intervention: Traditional consultation
Number of subjects: 402
Study 28432757 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine communication satisfaction
Number of subjects: 402
Study 26323444 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (CHX) digluconate and 0.05% cetylpyridinium chloride (CPC) solution
Number of subjects: 40
Study 26323444 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 40
Study 23518704 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain antisepsis (chlorhexidine disc at drain exit site and irrigation with dilute sodium hypochlorite solution)
Number of subjects: 100
Study 23518704 — intervention group
Group type: COMPARATOR
Intervention: Standard drain care (twice daily cleansing with alcohol swabs)
Number of subjects: 100
Study 21632472 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 1342
Study 21632472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1342
Study 19252449 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration salt solutions containing rice
Number of subjects: 30
Study 19252449 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration salt solutions containing amylase-resistant starch
Number of subjects: 30
Study 19252449 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration salt solutions containing glucose
Number of subjects: 30
Study 16682179 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (6mg bolus, max 12mg)
Number of subjects: 64
Study 16682179 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (5mg bolus, max 10mg)
Number of subjects: 64
Study 15186629 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass (LGBP)
Number of subjects: 80
Study 15186629 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic vertical banded gastroplasty (LVBG)
Number of subjects: 80
Study 11565401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercessory prayer
Number of subjects: 95
Study 11565401 — intervention group
Group type: COMPARATOR
Intervention: Positive visualization
Number of subjects: 95
Study 11565401 — intervention group
Group type: COMPARATOR
Intervention: Expectancy
Number of subjects: 95
Study 9450156 — intervention group
Group type: EXPERIMENTAL
Intervention: pivagabine, 900 mg/d for 90 days
Number of subjects: 186
Study 9450156 — intervention group
Group type: COMPARATOR
Intervention: placebo for 90 days
Number of subjects: 186
Study 7521828 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists
Number of subjects: 0
Study 3345636 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% bupivacaine aerosol
Number of subjects: 6
Study 3345636 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (saline) aerosol
Number of subjects: 6
Study 28671856 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg intravenously every 2 weeks
Number of subjects: 405
Study 28671856 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice chemotherapy (ICC; dacarbazine 1,000 mg/m2 every 3 weeks or carboplatin AUC 6 plus paclitaxel 175 mg/m2 every 3 weeks)
Number of subjects: 405
Study 28671856 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice chemotherapy (ICC)
Number of subjects: 405
Study 27392256 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet program 'Lose It' (recording daily calories and physical activity)
Number of subjects: 24
Study 27392256 — intervention group
Group type: COMPARATOR
Intervention: Daily wellness program (health tips delivered via e-mail)
Number of subjects: 24
Study 25179846 — intervention group
Group type: EXPERIMENTAL
Intervention: VITACORA-19 questionnaire
Number of subjects: 323
Study 25179846 — intervention group
Group type: EXPERIMENTAL
Intervention: VITACORA-19 scores
Number of subjects: 323
Study 25179846 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum important difference
Number of subjects: 323
Study 22520532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received enhanced in‐hospital counseling, attention to adherence barriers, communication of discharge medications to community pharmacists and physicians, and ongoing assessment of adherence by community pharmacists.
Number of subjects: 143
Study 22520532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 143
Study 22520532 — intervention group
Group type: COMPARATOR
Intervention: Control group received usual care with discharge counseling and a letter to the community physician.
Number of subjects: 143
Study 22520532 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143
Study 20846085 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigator providing social support
Number of subjects: 0
Study 18632105 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (30 mg/m2 intramuscularly weekly)
Number of subjects: 131
Study 18632105 — intervention group
Group type: COMPARATOR
Intervention: Actinomycin D (1.25 mg/m2 intravenous bolus every 2 weeks)
Number of subjects: 131
Study 18632105 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 131
Study 18632105 — intervention group
Group type: COMPARATOR
Intervention: Actinomycin D
Number of subjects: 131
Study 16837736 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 750 mg
Number of subjects: 20
Study 16837736 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 1000 mg
Number of subjects: 20
Study 16837736 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 1000 mg + Norethisterone enanthate (NETE) 200 mg
Number of subjects: 20
Study 16837736 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 12473978 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA)
Number of subjects: 80
Study 12473978 — intervention group
Group type: COMPARATOR
Intervention: Bethanecol
Number of subjects: 80
Study 12473978 — intervention group
Group type: COMPARATOR
Intervention: Biotene
Number of subjects: 80
Study 12473978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10081088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrastructural analysis of specialized conducting and working myocytes in the sinoatrial region of the human heart
Number of subjects: 45
Study 10081088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of light to dark myocytes in the sinus node
Number of subjects: 45
Study 7982257 — intervention group
Group type: EXPERIMENTAL
Intervention: Uni-Dur (600 mg once daily for 5 doses)
Number of subjects: 18
Study 7982257 — intervention group
Group type: COMPARATOR
Intervention: Theo-Dur (300 mg twice daily for 10 doses)
Number of subjects: 18
Study 7982257 — intervention group
Group type: EXPERIMENTAL
Intervention: Uni-Dur
Number of subjects: 18
Study 7982257 — intervention group
Group type: COMPARATOR
Intervention: Theo-Dur
Number of subjects: 18
Study 3276446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIG) in association with antibiotics
Number of subjects: 0
Study 3276446 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 0
Study 31028421 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal sacrospinous fixation with anterior mesh (VSF-AM)
Number of subjects: 71
Study 31028421 — intervention group
Group type: COMPARATOR
Intervention: Abdominal sacrocolpopexy (ASC)
Number of subjects: 71
Study 31724353 — intervention group
Group type: EXPERIMENTAL
Intervention: SU Jia-fu's Wenjing Tongdu external treatment combined with long-snake moxibustion at the governor vessel, twice a week for 8 weeks.
Number of subjects: 64
Study 31724353 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture and rehabilitation of bladder function (Control group).
Number of subjects: 64
Study 27923432 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 166
Study 27923432 — intervention group
Group type: COMPARATOR
Intervention: Alarms
Number of subjects: 166
Study 27923432 — intervention group
Group type: COMPARATOR
Intervention: Room temperature
Number of subjects: 166
Study 27923432 — intervention group
Group type: COMPARATOR
Intervention: Anxiety
Number of subjects: 166
Study 23818201 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrosis No.1 compound (Chinese herbal medicine)
Number of subjects: 162
Study 23818201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 21053054 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental amalgam fillings
Number of subjects: 0
Study 21053054 — intervention group
Group type: COMPARATOR
Intervention: Composite fillings
Number of subjects: 0
Study 19797813 — intervention group
Group type: EXPERIMENTAL
Intervention: Sago gel (SG)
Number of subjects: 12
Study 19797813 — intervention group
Group type: EXPERIMENTAL
Intervention: Sago porridge (SR)
Number of subjects: 12
Study 19797813 — intervention group
Group type: EXPERIMENTAL
Intervention: Sago paste (SP)
Number of subjects: 12
Study 19797813 — intervention group
Group type: COMPARATOR
Intervention: White bread (WB)
Number of subjects: 12
Study 19797813 — intervention group
Group type: EXPERIMENTAL
Intervention: Sago meals (SR, SP, SG)
Number of subjects: 12